The emergence of effectivedisease-modifying treatment options (ie, SGLT2 inhibitors and finerenone)providing cardiorenal protection for individuals with DKD has made the timelyidentification and treatment of this common comorbidity even more critical. This evidence concerns the gene SLC5A2 and diabetic kidney disease.